erlotinib for gallbladder cancer – pro
Literature contains a number of reprots of responses of gallbladder cancer to erlotinib, in cases with and without EGFR mutation. The phase II study by Mody concluded that his study Results suggest a therapeutic benefit for EGFR blockade with erlotinib in patients with biliary cancer. and that additional studies are necessary.Therefore, it remains E/I and not med necessary.
Mody K, Strauss E, Lincer R, Frank RC. Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report.BMC Cancer. 2010 Oct 20;10:570
Kabir Mody, Edward Strauss, Robert Lincer and Richard C Frank, Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report. BMC Cancer201010:570
https://www.nature.com/news/tissue-independent-cancer-drug-gets-fast-track-approval-from-us-regulator-1.22054, 2017